At a glance
ClinicalIndex Comparison RecordPhase 2Active· 88 enrolled
Drug / intervention
Trastuzumab +2 moredrug
Likely dose
Trastuzumab 8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Sep 9, 2013·Updated Jul 1, 2025
In Brief
A Phase 2 clinical trial evaluating Positron emission tomography (PET), Trastuzumab, and 1 other intervention for Breast Cancer. Active but no longer recruiting, targeting 88 participants across 10 sites.
Detailed Summary
This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which patients are most likely to respond to the combination of trastuzumab and pertuzumab when given prior to surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Timeline
Phase 2ActiveOverdue
2014201520162017201820192020202120222023202420252026
First PostedSep 2013
Enrollment StartJan 2014
Primary CompletionMar 2018
Study CompletionJun 2026
TodayJul 2026
First PostedSep 9, 2013
Enrollment StartJan 30, 2014
Primary CompletionMar 20, 2018
Study CompletionJun 1, 2026
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.8 years ago
Interventions
Positron emission tomography (PET)procedure
PET will be performed at baseline and on day 15
Trastuzumabdrug
8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
Pertuzumabdrug
840 mg as a loading dose, then 420 mg every 3 weeks, IV